PapersPMID:36593713
Efficacy and Safety of Maca (Lepidium meyenii) in Patients with Symptoms of Late-Onset Hypogonadism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“However, there was no statistically significant difference in serum total testosterone level between the two groups (Maca-treated and placebo) (p=0.444).”
- Study
- RCT
- Duration
- 3 months
- Dose studied
- 1,000 mg capsules, two tablets three times daily before food, about 5 g/day, 12 weeks
- Population
- Men over 40 with late-onset hypogonadism symptoms (AMS total score 27 or more) and morning serum total testosterone of at least 2.0 ng/mL
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Eugonadal men over 40 years with late-onset hypogonadism symptoms (AMS total score 27 or more) at two Korean hospitals; gelatinized maca (Lepidium meyenii) powder about 5 g/day versus lactose placebo for 12 weeks
- Participants
- 80
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 34